Abstract:Xinting Wang, 1, &ast Jiahui Yang, 1, &ast Cheng Lu, 2 Yinqin Hu, 1 Zhaohui Xu, 1 Qiqi Wan, 1 Meng Zhang, 1 Tianyun Shi, 1 Zhirui Liu, 1 Yongming Liu 1 1 Department of Cardiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200021, People's Republic of China; 2 Department of Cardiology, Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yongming Liu, Department of Cardiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No. 185, Pu'an Road, Huangpu District, Shanghai, 200021, People's Republic of China, Email Purpose: This study aimed to elucidate the protective mechanism of Traditional Chinese Medicine (TCM) Qifu Yixin formula (QFYXF) to improve heart failure (HF) by promoting β-arrestin2 (β-arr2)-mediated SERCA2a SUMOylation. Materials and Methods: The transverse aortic constriction (TAC)-induced HF mice were treated with QFYXF or carvedilol for 8 weeks. β-arr2-KO mice and their littermate wild-type (WT) mice were used as controls. Neonatal rat cardiomyocytes (NRCMs) were used in vitro. Cardiac function was evaluated by echocardiography and serum NT-proBNP. Myocardial hypertrophy and myocardial fibrosis were assessed by histological staining. β-arr2, SERCA2a, SUMO1, PLB and p-PLB expressions were detected by Western blotting, immunofluorescence and immunohistochemistry. SERCA2a SUMOylation was detected by Co-IP. The molecular docking method was used to predict the binding ability of the main active components of QFYXF to β-arr2, SERCA2a, and SUMO1, and the binding degree of SERCA2a to SUMO1 protein. Results: The HF model was constructed 8 weeks after TAC. QFYXF ameliorated cardiac function, inhibiting myocardial hypertrophy and fibrosis. QFYXF promoted SERCA2a expression and SERCA2a SUMOylation. Further investigation showed that QFYXF promoted β-arr2 expression, whereas Barbadin (β-arr2 inhibitor) or β-arr2-KO reduced SERCA2a SUMOylation and attenuated the protective effect of QFYXF improved HF. Molecular docking showed that the main active components of QFYXF had good binding activities with β-arr2, SERCA2a, and SUMO1, and SERCA2a had a high binding degree with SUMO1 protein. Conclusion: QFYXF improves HF by promoting β-arr2 mediated SERCA2a SUMOylation and increasing SERCA2a expression. Keywords: heart failure, Qifu Yixin Formula, β-arrestin2, SERCA2a, SUMOylation The 2022 AHA/ACC/HFSA definition heart failure (HF) is a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. 1 There are more than 64.3 million patients with HF worldwide, 2 and the mortality rate of HF patients is as high as 50% within 5 years. HF has become the leading global public health problem due to its high incidence, high rate of rehospitalization, high mortality, poor quality of life, and high-cost treatment. 3 Reduced expression and activity of sarco/endoplasmic reticulum Ca2 + -ATPase 2a (SERCA2a) is one of the hallmarks and key pathological mechanisms of HF. 4 Sarcoplasmic reticulum is an organelle that stores Ca 2+ and mediates the release and re-uptake of Ca 2+ during contraction and relaxation. SERCA2a mediates the re-entry of Ca 2+ in the cytoplasm into sarcoplasmic reticulum, regulating cardiac systolic and diastolic function. Gene therapy that increases the expression and activity of SERCA2a in the heart has been proven to be an effective strategy for treating HF. Although targeting SERCA2a has become a research hotspot in the treatment of HF, the efficacy of SERCA2a gene therapy in clinical trials of HF is not satisfactory. 5 Therefore, it is of great clinical significance to find effective drugs to improve SERCA2a expression and activity to treat HF and to clarify the upstream regulatory mechanisms of SERCA2a. SERCA2a expression is also regulated by post-translational modifications (PTMs). Small ubiquitin-like modifier (SUMO)ylation is a ubiquitin-like reversible PTM. Research studies have shown that the SUMO1 (not SUMO2/3) and SUMOylation of SERCA2a in HF patients are significantly reduced, thereby reducing SERCA2a expression. 6 Adenovirus mediated overexpression of SUMO1 increased the expression of SERCA protein in the heart of transverse aortic constriction (TAC) induced HF mice and improved cardiac function. On the other hand, shRNA knockd -Abstract Truncated-

Qifu Yixin Formula Improves Heart Failure by Enhancing β-Arrestin2 Mediated the SUMOylation of SERCA2a

Analysis of Microrna Expression Profiles Induced by Yiqifumai Injection in Rats with Chronic Heart Failure

Cardiomyocytes Deficiency of SENP1 Promotes Myocardial Fibrosis Via Paracrine Action

Qishenyiqi Protects Ligation-Induced Left Ventricular Remodeling By Attenuating Inflammation And Fibrosis Via Stat3 And Nf-Kappa B Signaling Pathway

Abstract 9763: Cardiac Beta-arrestin2 Promotes Contractility by Enhancing SERCA2a SUMOylation and Activity

LuQi Formula attenuates Cardiomyocyte ferroptosis via activating Nrf2/GPX4 signaling axis in heart failure.

Rg3 promotes the SUMOylation of SERCA2a and corrects cardiac dysfunction in heart failure

Shen'ge Formula Protects Cardiac Function in Rats with Pressure Overload-Induced Heart Failure

Retracted: the Correlation Between Angiogenesis and Abnormal Expression of SERCA2a, Phospholamban and the Endothelin Pathway in Heart Failure, and Improvement by Puerarin

Network and Experimental Pharmacology on Mechanism of Yixintai Regulates the TMAO/PKC/NF-κB Signaling Pathway in Treating Heart Failure

The Protective Effect of Qishen Granule on Heart Failure after Myocardial Infarction through Regulation of Calcium Homeostasis

Bushen Huoxue Yiqi formula alleviates cardiac fibrosis in ischemic heart failure through SIRT1/Notch1 pathway-mediated EndMT

Effects and mechanism of Compound Qidan Formula on rats with HFpEF induced by hypertension and diabetes mellitus based on Ang Ⅱ/TGF-β1/Smads signaling pathway

Astragaloside IV alleviates heart failure by regulating SUMO-specific protease 1

YiQiFuMai powder injection ameliorates chronic heart failure through cross-talk between adipose tissue and cardiomyocytes via up-regulation of circulating adipokine omentin

Proteomic Analysis Reveals the Protective Effects of Yiqi Fumai Lyophilized Injection on Chronic Heart Failure by Improving Myocardial Energy Metabolism

YiQiFuMai Powder Injection attenuates coronary artery ligation-induced myocardial remodeling and heart failure through modulating MAPKs signaling pathway

QiShenYiQi Pill Ameliorates Cardiac Fibrosis After Pressure Overload-Induced Cardiac Hypertrophy by Regulating FHL2 and the Macrophage RP S19/TGF-β1 Signaling Pathway

Multi-omics approach for identification of molecular alterations of QiShenYiQi dripping pills in heart failure with preserved ejection fraction

Luhong Formula and Hydroxysafflor yellow A protect cardiomyocytes by inhibiting autophagy

Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR-181a in a Rodent Chronic Myocardial Infarction Model.